By: Benzinga
Aegis Capital Reiterates Buy on Valeant Pharmaceuticals International on Obagi Acquisition
In a report published Wednesday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating and $80.00 price target on Valeant Pharmaceuticals International (NYSE: VRX ). In the report, Selvaraju noted, “Once more, Valeant has lived up to its reputation as perhaps the most acquisitive company in the pharmaceutical sector. This
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here